Both motor and somatosensory recovery were significantly improved at 28 days after stroke in the G-CSF treated group and in the two groups with a combination of concomitant or sequential treatment with G-CSF and CIMT while CIMT only just narrowly failed the significance level [6]. This evidence concerns the gene CSF3 and stroke disorder.